Orexigen's MysimbaTM receives positive CHMP opinion recommending approval in EU
Orexigen announced the Committee for Medicinal Products For Human Use of the EMA has adopted a positive opinion recommending the granting of a centralized marketing authorization for Mysimba™ (naltrexone HCI / bupropion HCI prolonged release) for management of weight in adult patients. December 19, 2014